Biotech company Rigvir Group, who owns a registered oncolytic virotherapy medicine (RIGVIR^®) is looking for partners globally to finance the commercialization process of a next generation solution for unmet medical needs in oncology based on the existing product.

We have elaborated a registration roadmap for unmet medical needs – early Melanoma and Uveal Melanoma treatment – considering the following:

• Medical need – currently no treatment solutions for both early Melanoma and Uveal Melanoma;
• Target market value exceeds 4.5 Billion EUR annually;
• Company owns a unique and well-established treatment method;
• Company owns a GMP API production and know-how;
• RIGVIR^® has Excellent safety profile;
• New projects are supported by preclinical data and retrospective clinical observations;
• The production and use of ECHO7 virus RIGVIR^® have granted strong international IP protection;
• The Company has authorization to start any Phase II clinical trials in the EU.

It is expected that the company value would rise 3 times within the next two years but in 5 to 7 years period – 10 times, at least.

Information Request